Table 3.
Risk analysis of graft failure.
| Univariate HR (95% CI) |
p-Value | Multivariate † HR (95% CI) |
p-Value | |
|---|---|---|---|---|
| Induction therapy: r-ATG/Basiliximab | 0.70 (0.09–5.49) | 0.737 | 0.64 (0.08–5.03) | 0.670 |
| Recipient age | 1.00 (0.95–1.05) | 0.903 | ||
| BMI | 1.08 (0.91–1.28) | 0.403 | ||
| sex: male/female | 1.66 (0.45–6.12) | 0.450 | ||
| DM | 1.86 (0.56–6.22) | 0.315 | 1.48 (0.44–4.98) | 0.525 |
| HLA 1 mismatch | 1.22 (0.74–2.00) | 0.442 | ||
| HLA 2 mismatch | 1.77 (0.75–4.18) | 0.192 | 1.40(0.57–3.42) | 0.462 |
| WIT | 0.95 (0.58–1.58) | 0.854 | ||
| CIT | 0.99 (0.97–1.01) | 0.375 | ||
| Donor age | 0.97 (0.93–1.02) | 0.267 | ||
| creatinine | 1.58 (0.22–10.0) | 0.686 | ||
| sex: male/female | 1.42 (0.45–4.48) | 0.552 | ||
| CMV antigenemia > 50/400,000 | 0.04 (0.00–639) | 0.523 | ||
| BKV viremia | 10.91 (0.20–4.17) | 0.908 | ||
| BPAR | 6.72 (1.47–30.8) | 0.014 | 5.89 (1.25–27.8) | 0.025 |
r-ATG, rabbit anti-thymocyte globulin; BMI, body mass index; DM, diabetes mellitus; HLA, human leukocyte antigen; PRA, panel reactive antibody; CMV, cytomegalovirus; BKV, polyomavirus BK; BPAR, biopsy-proven acute rejection; †: Only one variable has p-value lower than 0.1, so alternative criteria (p < 0.4 and HR > 1.29 or < 0.77) was applied for selection of variables in multivariate analysis. Three variables plus variable ‘induction therapy’ was included.